Importantly, a 92% reduction in tumor multiplicity was found in Ptgis-overexpressing mice [33] and prostacyclin analogs are currently in use for human NSCLC clinical trials in the National Cancer Institute Lung Cancer Biomarker and Chemoprevention Consortium. Here, PTGIS is linked to non-small cell lung carcinoma.